Source Articles
Atezolizumab
Showing 4 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Giordano et al. | 2026 | Prospective | A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis | 10.1007/s10549-026-07932-6 | NCT03483012 | 6 | 46.0 | Breast cancer | metastatic | Anti-PD-(L)1 mAb | Atezolizumab | — | 19 | intra-cranial | brain | — | 20 | 20.0 | 20.0 | 1 | 1 | 1 | 20 | 20 | 20 | Treatment-rel. | — | — | 0 | — | — | — | — |
| Levy et al. | 2025 | Prospective | Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. | 10.1038/s41392-025-02173-3 | NCT02992912 | 55 | 54.0 | Sarcoma | oligometastatic, metastatic | Anti-PD-(L)1 mAb | Atezolizumab | — | 72 | extra-cranial | lung, bone, other | Missing | 41 | 30.0 | 45.0 | 3 | 3 | 3 | Missing | 10 | 15 | Treatment-rel. | — | — | 1 | any G3: 1 AE | any G3: 1 pt | any G3: elevated CPK | — |
| Levy et al. | 2024 | Prospective | An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer | 10.1186/s12943-024-01970-8 | NCT02992912. | 54 | 59.0 | Colorectal cancer | metastatic | Anti-PD-(L)1 mAb | Atezolizumab | — | Missing | extra-cranial | liver, lung | peritoneal cavity and other sites (not specified) | 45 | 21.0 | 45.0 | 3 | Missing | Missing | Missing | Missing | Missing | RT-related | 0 | — | — | 0 | 0 | — | — |
| Horndalsveen et al. | 2023 | Prospective | Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial | 10.1002/1878-0261.13330 | NCT03644823 | 21 | 61.7 | Lung cancer | — | Anti-PD-(L)1 mAb | Atezolizumab | — | — | extra-cranial | lung | adrenal gland, liver, brain, | 18 | — | — | 3 | — | — | 6 | — | — | Treatment-rel. | — | — | 3 | any G3: 3 AE | any G3: 3 pt | any G3: colitis, pneumonitis, skin toxicity | — |